Xeris to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced its participation in three upcoming investor conferences in September 2024. The company will attend the 2024 Wells Fargo Healthcare Conference in Boston on September 4 for meetings only. At the H.C. Wainwright 26th Annual Global Investor Conference in New York on September 10, Xeris will participate in meetings and a fireside chat at 3:30pm ET. Lastly, the company will be present at the 2024 Cantor Global Healthcare Conference in New York on September 18 for meetings only.

Investors interested in 1x1 meetings should contact the conference sponsors directly. A webcast of the fireside chat will be available on Xeris' investor relations website. This participation in multiple conferences demonstrates Xeris' commitment to engaging with investors and showcasing its growth-oriented biopharmaceutical business.

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events:

• 2024 Wells Fargo Healthcare Conference, Boston, MA
  • Meetings only on September 4, 2024
• H.C. Wainwright 26^th Annual Global Investor Conference, New York, NY
  • Meetings and fireside chat on September 10, 2024 at 3:30pm ET
• 2024 Cantor Global Healthcare Conference, New York, NY
  • Meetings only on September 18, 2024

Please check with each conference sponsor to arrange 1x1 meetings.

Webcast information for the fireside chat will be available at https://xerispharma.com/investor-relations.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect®, to support long-term product development and commercial success.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow Xeris on Twitter, LinkedIn or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240822640280/en/

Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com

Source: Xeris Biopharma Holdings, Inc.

FAQ

What investor conferences will Xeris Biopharma (XERS) attend in September 2024?

Xeris Biopharma (XERS) will attend three investor conferences in September 2024: the Wells Fargo Healthcare Conference in Boston on September 4, the H.C. Wainwright Global Investor Conference in New York on September 10, and the Cantor Global Healthcare Conference in New York on September 18.

Will Xeris Biopharma (XERS) present at any of the September 2024 investor conferences?

Yes, Xeris Biopharma (XERS) will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investor Conference on September 10, 2024, at 3:30pm ET in New York.

How can investors access the webcast of Xeris Biopharma's (XERS) fireside chat?

Investors can access the webcast of Xeris Biopharma's (XERS) fireside chat through the company's investor relations website at https://xerispharma.com/investor-relations.

How can investors arrange 1x1 meetings with Xeris Biopharma (XERS) at these conferences?

Investors interested in arranging 1x1 meetings with Xeris Biopharma (XERS) should contact the respective conference sponsors directly to schedule these meetings.